Prolong's Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran

SOUTH PLAINFIELD, N.J., Dec. 15, 2011 /PRNewswire/ -- Prolong Pharmaceuticals today announced that Tom Flachmeyer has joined Prolong to spearhead the firms' engineering and facilities planning function for it oxygen therapeutic product SANGUINATE.   Having previously directed the construction of the world's largest biotech facility to date, Wyeth's Grange Castle facility in Dublin, Ireland, Flachmeyer is charged with expanding Prolong's current cGMP production facility to support worldwide clinical development in sickle cell patients.

Tom brings an extensive background in managing technical organizations, strategic / capital planning and capital project execution and has a proven track record of executing technically complex projects. Formerly a Director of Project Management at Parsons, Life Sciences Group, Tom has held senior management positions in Engineering at Wyeth, Warner-Lambert (now Pfizer) and Foster Wheeler.  At Schering Plough he spent 5 years in Ireland and 3 years in Singapore executing large scale capital projects that delivered critical capabilities to the supply chain.

"Tom's international experience in designing high quality, large scale bio-manufacturing facilities to FDA approved status, is unparalleled in the industry," said Glenn Kazo, Prolong's President. "As lead project manager for several multinational engineering firms, and with direct experience as a bio-pharma company executive, Tom is ideally suited to drive our expansion." 

About Prolong Pharmaceuticals
Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. First founded in 2002 as a research company Prolong is focused on sickle cell anemia, diabetic ischemia, and several trauma indications. The company's senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. For more information visit: www.prolongpharmaceuticals.com.

 

SOURCE Prolong Pharmaceuticals

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.